Background: Currently, oral targeted therapies are known to be effective and are frequently used to treat\nmetastatic cancer patients, but fatigue is a frequently reported early side effect of these treatments. This fatigue\nmay impact the patientâ??s treatment adherence and result in a negative impact on quality of life. Physical exercise\nsignificantly improved the general well-being and quality of life of advanced cancer patients. However, there is no\nspecific physical activity program adapted for patients with advanced disease.\nMethods: QUALIOR is a two-part, randomized, open-label, and multicenter with two arms phase II/III trial. Patients\n(phase II: n = 120; phase III: n = 312) with metastatic cancer (breast cancer, kidney cancer, lung cancer, and other\ncancers [including but not limited to colon cancer, melanoma, sarcoma, or hepatocarcinoma]) treated with a firstor\nsecond-line oral targeted therapy without chemotherapy will be included. Patients will be randomized (2:1) to a\n3-month supervised home-based standardized physical activity program or to a recommended adapted physical\nactivity (via a booklet). The primary objective of the phase II is to evaluate the feasibility of the supervised program.\nThe primary objective of the phase III is the evaluation of the benefit of the supervised home-based program\ncompare to the recommended program in terms of fatigue and quality of life at 3 months. The secondary\nobjectives aim to evaluate the impact of the supervised program on fatigue over time, pain, physical capacities,\npsychosocial and cognitive functions, general quality of life, frequency of dose reduction and patientsâ?? adherence to\nthe targeted therapy, overall survival, and progression-free survival. This study will also evaluate the medicoeconomic\nimpact of supervised program...........................
Loading....